Condition: Mature B-cell Malignancies · Sponsor: InnoCare Pharma Inc.
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
This description comes directly from the study's public registry record.
Study Director · 609-524-1106 · ICP-CL-1202general@innocarepharma.com
Always discuss trial participation with your own doctor first.
| BRCR Medical Center | Plantation, Florida, United States | Recruiting |
| Clinical Research Alliance | Westbury, New York, United States | Recruiting |
| Pan American Center for Oncology Trials | San Juan, Puerto Rico | Recruiting |
| CNE CCOHTPC of Cherkasy Regional Council | Cherkasy, Ukraine | Recruiting |
| CNE"City Clin Hosp#4"of Dnipro City Council | Dnipro, Ukraine | Recruiting |
| Medical Center of Limited Liability Company Arensia Exploratory Medicine | Kyiv, Ukraine | Recruiting |
| Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC | Kyiv, Ukraine | Recruiting |
| SI Institute of Blood Pathology and Transfusion Medicine of AMSU | Lviv, Ukraine | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06351527